Evidence map›Paper›PMID 38658627›Full record

ArticleScientific reports2024

A nanowell platform to identify, sort and expand high antibody-producing cells.

Fikri Abali, Richard Schasfoort, Sanne Nijland, Jelle Wittenberns, Arjan G J Tibbe, Marcel den Hartog, Louis Boon, Leon W M M Terstappen

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Fikri AbaliDepartment of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, PO Box 217, 7500AE, Enschede, The Netherlands.
Richard SchasfoortDepartment of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, PO Box 217, 7500AE, Enschede, The Netherlands.
Sanne NijlandVYCAP, Capitool 41, 7521PL, Enschede, The Netherlands.
Jelle WittenbernsPolpharma Biologics Utrecht B.V., Yalelaan 46, 3584 CM, Utrecht, The Netherlands.
Arjan G J TibbeVYCAP, Capitool 41, 7521PL, Enschede, The Netherlands.
Marcel den HartogPolpharma Biologics Utrecht B.V., Yalelaan 46, 3584 CM, Utrecht, The Netherlands.
Louis BoonJJP Biologics, Bobrowiecka 6, 00-728, Warsaw, Poland.
Leon W M M TerstappenDepartment of Medical Cell BioPhysics, Faculty of Science and Technology, University of Twente, PO Box 217, 7500AE, Enschede, The Netherlands. l.w.m.m.terstappen@utwente.nl.
Novay · NLPolpharma Biologics (Netherlands) · NLUniversity of Twente · NLHeinrich Heine University Düsseldorf · DE

Funding

NWO, The Netherlands Organization for Scientific Research . Project McSPRinter under project number 15327
6 · The paper itself

Abstract

Increased use of therapeutic monoclonal antibodies and the relatively high manufacturing costs fuel the need for more efficient production methods. Here we introduce a novel, fast, robust, and safe isolation platform for screening and isolating antibody-producing cell lines using a nanowell chip and an innovative single-cell isolation method. An anti-Her2 antibody producing CHO cell pool was used as a model. The platform; (1) Assures the single-cell origin of the production clone, (2) Detects the antibody production of individual cells and (3) Isolates and expands the individual cells based on their antibody production. Using the nanowell platform we demonstrated an 1.8-4.5 increase in anti-Her2 production by CHO cells that were screened and isolated with the nanowell platform compared to CHO cells that were not screened. This increase was also shown in Fed-Batch cultures where selected high production clones showed titers of 19-100 mg/L on harvest day, while the low producer cells did not show any detectable anti-Her2 IgG production. The screening of thousands of single cells is performed under sterile conditions and the individual cells were cultured in buffers and reagents without animal components. The time required from seeding a single cell and measuring the antibody production to fully expanded clones with increased Her-2 production was 4-6 weeks.

Indexed as

Antibodies, MonoclonalCricetulusErb-b2 Receptor Tyrosine KinasesAnimalsAntibody-Producing CellsCell SeparationCHO CellsHumansSingle-Cell AnalysisAntibodies, MonoclonalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesAntibody secretionCHO cellsClonal expansionNanowell chipSingle-cell analysis

Identifiers

PMID38658627
PMCPMC11043069
OpenAlexW4395071314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.